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ABSTRACT 
Migraine is a chronic neurological disorder with several trigger factors including dietary, hormonal and environmental factors. Migraine is a 
primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one-half of the 
head, are pulsating in nature, and last from two to 72 hours. Nitrates, such as cardiac therapeutics and food additives, are common headache 
triggers, with nitric oxide playing an important role. Trigger factors are frequent in migraine patients, it avoidance may decrease headache 
frequency and also improve patients quality of life. Facultative anaerobic bacteria in the oral cavity may contribute migraine-triggering levels of 
nitric oxide through the salivary nitrate-nitrite-nitric oxide pathway. 
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INTRODUCTION 
Migraine is a massively common and impairing primary 
headache disorder, which was ranked the third highest cause 
of disability among the population under 50 years of age by 
the Global Burden of Disease studies. It is conceptualized as a 
multiphasic neurobiological disorder, which is characterized 
by various accompanying symptoms besides pain, such as 
phonophobia, photophobia, nausea, vomiting or cutaneous 
allodynia. Although these symptoms often occur 
simultaneously with headache, several behavioural, affective 
and cognitive symptoms exist, which follow a specific 
sequence over time and start days before7 or after the 
migraine attack. Changes in appetite or in mood, yawning or 
fatigue typically precede the attacks, while, for example 
fatigue, tiredness, euphoria or dysphoria frequently follow 
the headache. Several findings of advanced neuroimaging 
supported this assumption, identifying brain structural and 
functional alterations in migraineurs compared to healthy 
controls, not just during migraine attacks,  but in interictal 
stages too. Interracial imaging showed for example 
reductions in frontal and parietal lobe density along with an 
executive function deficit in set-shifting task; and an 
enhanced reactivity of the visual cortex after visual 
stimulation. These alterations are often positively correlated 
with disease duration and headache frequency. More than 
half of migraines in women occur right before, during, or 
after a women has her period. This often is called Menstrual 
migraine. But just a small fraction of women who have 
migraine headaches at other times of the month as well. Just 
before the cycle begins, level of the female hormones, 
(estrogen and progesterone) go down sharply. This drop in 
hormones may trigger a migraine because estrogen controls 
chemicals in the brain that affect a women’s pain sensation. 
NITRATE ASSOCIATIONS WITH HEADACHES AND 
MIGRAINES 
Nitrate-containing compounds have been identified as 
normal headache triggers. Food preservatives are frequently 
identified triggers for those who suffer from migraines (1). 
There are two differing mechanisms behind these two 
headache types. Immediate headaches appear to be 
connected to nitric oxide (NO)-mediated vasodilatation; in 
contrast, delayed migraines, similarly to migraines caused by 
foods, stress, and other factors, appear to be activated by the 
release of calcitonin gene-related peptide (CGRP), glutamate, 
cyclic GMP (cGMP), or S-nitrosylation-mediated changes in 
ion channel function (2). Nitrate-induced headaches manifest 
in one of two ways: “immediate” headaches with mild to 
medium severity growing within an hour of medication 
ingestion and “delayed” headaches happening 3 to 6 h after 
nitrate intake that are much more acute, with migrainelike 
symptoms (3,4). Also, cardiac medications containing 
nitrates may cause severe headaches, which occur in over 
80% of patients taking them. Indeed, just about 10% of 
patients cannot tolerate nitrate therapies due to intolerable 
headaches (5). Detain migraines appear to be dose 
dependent and are more likely to occur in individuals with a 
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family history of migraines (6). Notably, S-nitrosylation is 
dependent on the presence of NO. 
Nitrate-reducing bacteria in the oral and fecal samples of 
the AGP Because only bacteria, and not human cells, can 
reduce nitrate to nitrite (7). this may represent a symbiotic 
relationship by which our oral microbes maintain 
cardiovascular health using molecules present in our food. It 
has also been reported that in murine macrophages in vitro, 
the bacterial nitric oxide reductase NorB increases the 
decomposition rate of S-nitrosothiol (SNO) (8). This 
represents a potential connection between nitric oxide 
reductases and nitrate-induced migraines. Therefore, we 
determined the presence and abundance of nitrate, nitrite, 
and nitric oxide reductase genes in predicted metagenomes 
from stool and oral samples in the American Gut Project 
(AGP) cohort and correlated these genes with self-reported 
migraine status. 
CAUSE 
The underlying causes of migraines are unknown. However, 
they are believed to be related to a mix of environmental and 
genetic factors. They run in families in about two-thirds of 
cases (5) and rarely occur due to a single gene defect. While 
migraines were once believed to be more common in those 
of high intelligence, this does not appear to be true. A 
number of psychological conditions are associated, including 
depression, anxiety, and bipolar disorder, as are many 
biological events or triggers. 
SIGNS AND SYMPTOMS 
Migraines typically present with self-limited, recurrent 
severe headache associated with autonomic symptoms. 
About 15–30% of people with migraines experience 
migraines with an aura and those who have migraines with 
aura also frequently have migraines without aura. The 
severity of the pain, duration of the headache, and frequency 
of attacks are variable. A migraine lasting longer than 72 
hours is termed status migrainosus. There are four possible 
phases to a migraine, although not all the phases are 
necessarily experienced:  
 The prodrome, which occurs hours or days before the 
headache 
 The aura, which immediately precedes the headache 
 The pain phase, also known as headache phase 
 The postdrome, the effects experienced following the 
end of a migraine attack 
Migraines are associated with major depression, bipolar 
disorder, anxiety disorders, and obsessive compulsive 
disorder. These psychiatric disorders are approximately 2–5 
times more common in people without aura, and 3–10 times 
more common in people with aura.  
Prodrome phase 
Prodromal or premonitory symptoms occur in about 60% of 
those with migraines, with an onset that can range from two 
hours to two days before the start of pain or the aura. These 
symptoms may include a wide variety of phenomena, 
including altered mood, irritability, depression or euphoria, 
fatigue, craving for certain food(s), stiff muscles (especially 
in the neck), constipation or diarrhea, and sensitivity to 
smells or noise. This may occur in those with either migraine 
with aura or migraine without aura. 
Aura phase 
An aura is a transient focal neurological phenomenon that 
occurs before or during the headache. Auras appear 
gradually over a number of minutes and generally last less 
than 60 minutes. Symptoms can be visual, sensory or motor 
in nature and many people experience more than one. Visual 
effects occur most frequently; they occur in up to 99% of 
cases and in more than 50% of cases are not accompanied by 
sensory or motor effects. 
Pain phase 
Classically the headache is unilateral, throbbing, and 
moderate to severe in intensity. It usually comes on 
gradually and is aggravated by physical activity. In more than 
40% of cases, however, the pain may be bilateral and neck 
pain is commonly associated with it. Bilateral pain is 
particularly common in those who have migraines without 
an aura. Less commonly pain may occur primarily in the back 
or top of the head. The pain usually lasts 4 to 72 hours in 
adults,  
Postdrome 
The migraine postdrome could be defined as that 
constellation of symptoms occurring once the acute 
headache has settled. Many report a sore feeling in the area 
where the migraine was, and some report impaired thinking 
for a few days after the headache has pas sed. The person 
may feel tired or "hung over" and have head pain, cognitive 
difficulties, gastrointestinal symptoms, mood changes, and 
weakness. According to one summary, "Some people feel 
unusually refreshed or euphoric after an attack, whereas 
others note depression and malaise." For some individuals 
this can vary each time.  
DIAGNOSIS 
If you have migraines or a family history of migraines, a 
doctor trained in treating headaches (neurologist) will likely 
diagnose migraines based on your medical history, 
symptoms, and a physical and neurological examination. 
 Blood tests - Your doctor may order these to test for 
blood vessel problems, infections in your spinal cord or 
brain, and toxins in your system. 
 Magnetic resonance imaging (MRI): An MRI uses a 
powerful magnetic field and radio waves to produce 
detailed images of the brain and blood vessels.  
MRI scans help doctors diagnose tumors, strokes, 
bleeding in the brain, infections, and other brain and 
nervous system (neurological) conditions. 
 Computerized tomography (CT) scan: A CT scan uses 
a series of X-rays to create detailed cross-sectional 
images of the brain. This helps doctors diagnose 
tumors, infections, brain damage, bleeding in the brain 
and other possible medical problems that may be 
causing headaches. 
 Spinal tap (lumbar puncture): Your doctor may 
recommend a spinal tap (lumbar puncture) if he or she 
suspects infections, bleeding in the brain or another 
underlying condition. 
In this procedure, a thin needle is inserted between two 
vertebrae in the lower back to remove a sample of 
cerebrospinal fluid for analysis in a lab. 
TREATMENT 
Self-care 
 Common triggers include alcohol, caffeine or poor 
sleep. 
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 Pursuing an enjoyable activity or frustration to reduce 
stress and improve mental health. 
 Good sleep practices include having a regular bedtime 
schedule and avoiding naps, mobile and TV before 
bedtime. 
 Adjusting diet to reduce triggers causing disease 
dietary deficiencies. 
Many medications have been designed to treat 
migraines. Some drugs often used to treat other 
conditions also may help relieve or prevent migraines.  
 Over the years there have been positive developments 
in acute medication for migraine. These treatments 
can’t stop you from getting migraine but they can 
reduce your pain and other symptoms. 
 Drugs called triptans have been designed especially for 
migraine attacks. Their main effect is to reduce pain 
information coming to the brain. 
1. Anti-emetics (Anti-sickness): Metoclopramide, 
Domperidone, Prochlorperazine, [Anti-emetics relieve the 
nausea associated with migraine attacks] 
2. Serotonin (5-HT1) agonists or ‘Triptans’ : 
Sumatriptan, Almotriptan, Eletriptan, Frovatriptan, 
Naratriptan, Rizatriptan, Zolmitriptan, [Selective 5-
HT1 agonists relieve pain by narrowing blood vessels in the 
head and blocking the transmission of pain in sensory nerves 
supplying the skin and structures of the face] 
3. Tricyclic antidepressants (TCAs): Amitriptyline, 
Nortriptiline 
These drugs were previously used for depression, however, 
they are also effective at preventing migraine. They can be 
helpful in people with migraine who also have difficulty 
sleeping. 
Tricyclic antidepressants are thought to: 
 Block the re-uptake of 5-HT and norepinephrine 
 May block 5-HT2 receptors. 
4. Analgesics: Aspirin, Aceclofenac, Diclofenac, Tolfenamic 
acid, Naproxen, Paracetamol 
CONCLUSIONS 
Many people continue to have migraine attacks in older age. 
Special attention should be paid to the diagnosis of new 
migraine-like symptoms, especially visual migraine 
symptoms without headache. Any other co-existing health 
conditions have an important role not only in diagnosis but 
also in treatment choices. Acute and preventative medication 
should be chosen carefully. Effective treatment is available 
and, as for all age groups, careful management improves the 
quality of life. 
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